In February 2009, the BC Prenatal Genetic Screening Program adopted a serum-based approach to prenatal genetic screening with nuchal translucency (NT) ultrasound added for women at higher risk of having a fetus with Down syndrome or trisomy 18 and women with multiple gestations. Since the launch of the program, we have made significant progress in the implementation of NT ultrasound sites increasing our capacity to offer Integrated Prenatal Screening (IPS) (NT plus first and second trimester serum markers) to a larger proportion of women at higher risk. In addition, our commitment to provide screening that is evidence-based means that we must adjust our approach as new evidence is published.

This newsletter will focus on:
- Changes to the Guideline: Prenatal Screening for Down Syndrome,
- Information on current utilization
- Answers to Frequently Asked Questions
- Practical points
- The tables and algorithms enclosed with this newsletter REPLACE those distributed with the Guideline in February 2009. The updated Guideline (in PDF) reflecting these January 2010 changes is available for download on our website (www.bcprenatalscreening.ca).

**CHANGES TO THE SCREENING GUIDELINE:**

1. **New eligibility criteria for NT ultrasound (as part of IPS):**
   - As of January 2010, the following women qualify for NT ultrasound to be done in conjunction with first and second trimester serum markers (IPS):
     - Women ≥ 36 years old at expected date of delivery (EDD);
     - Women with twin pregnancies;
     - Women who have a history of a previous child or fetus with Down syndrome, trisomy 18 or trisomy 13;
     - Women ≥ 35 years old with 3 or more miscarriages;
     - Women who are HIV positive; and
     - Women pregnant following In vitro fertilization and intracytoplasmic sperm injection.

2. **Screening in twin pregnancies:**
   - Based on published studies, screening twin pregnancies with both NT ultrasound and serum markers reduces the false positive rate while maintaining a high detection rate as compared to NT ultrasound alone.
   - As of January 2010, women pregnant with twins should be screened by NT ultrasound and first and second trimester serum markers (IPS). If NT is not available, SIPS should be offered. If the patient presents after 13 weeks 6 days gestation, Quad should be offered. Women who are ≥35 years old have the option of amniocentesis without prior screening.

---

**BC PRENATAL GENETIC SCREENING PROGRAM UPDATE**

In February 2009, the BC Prenatal Genetic Screening Program adopted a serum-based approach to prenatal genetic screening with nuchal translucency (NT) ultrasound added for women at higher risk of having a fetus with Down syndrome or trisomy 18 and women with multiple gestations. Since the launch of the program, we have made significant progress in the implementation of NT ultrasound sites increasing our capacity to offer Integrated Prenatal Screening (IPS) (NT plus first and second trimester serum markers) to a larger proportion of women at higher risk. In addition, our commitment to provide screening that is evidence-based means that we must adjust our approach as new evidence is published.

This newsletter will focus on:
- Changes to the Guideline: Prenatal Screening for Down Syndrome, Trisomy 18 and Neural Tube Defects
- Information on current utilization
- Answers to Frequently Asked Questions
- Practical points

The tables and algorithms enclosed with this newsletter REPLACE those distributed with the Guideline in February 2009. The updated Guideline (in PDF) reflecting these January 2010 changes is available for download on our website (www.bcprenatalscreening.ca).

**CHANGES TO THE SCREENING GUIDELINE:**

1. **New eligibility criteria for NT ultrasound (as part of IPS):**
   - As of January 2010, the following women qualify for NT ultrasound to be done in conjunction with first and second trimester serum markers (IPS):
     - Women ≥ 36 years old at expected date of delivery (EDD);
     - Women with twin pregnancies;
     - Women who have a history of a previous child or fetus with Down syndrome, trisomy 18 or trisomy 13;
     - Women ≥ 35 years old with 3 or more miscarriages;
     - Women who are HIV positive; and
     - Women pregnant following In vitro fertilization and intracytoplasmic sperm injection.

2. **Screening in twin pregnancies:**
   - Based on published studies, screening twin pregnancies with both NT ultrasound and serum markers reduces the false positive rate while maintaining a high detection rate as compared to NT ultrasound alone.
   - As of January 2010, women pregnant with twins should be screened by NT ultrasound and first and second trimester serum markers (IPS). If NT is not available, SIPS should be offered. If the patient presents after 13 weeks 6 days gestation, Quad should be offered. Women who are ≥35 years old have the option of amniocentesis without prior screening.

---

**Nuchal Translucency (NT) Ultrasound**

Since February 2009, numerous sonographers and sonologists have undergone training and certification for providing nuchal translucency ultrasound. Increasing the number of certified NT sites in BC has lead to a significant improvement in access and eligibility for NT. Eligible women can have an NT ultrasound done at any of the following NT sites:

<table>
<thead>
<tr>
<th>City</th>
<th>Site</th>
<th>Booking Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kelowna</td>
<td>Kelowna Regional Fertility Centre</td>
<td>250-861-4011, 250-861-6814</td>
</tr>
<tr>
<td>New Westminster</td>
<td>Royal Columbian Hospital in Medical Imaging area</td>
<td>604-520-4132</td>
</tr>
<tr>
<td>North Vancouver</td>
<td>North Shore Medical Imaging</td>
<td>604-867-3729 (XRAY), F: 604-864-0365</td>
</tr>
<tr>
<td>Prince Rupert</td>
<td>Prince Rupert Regional Hospital</td>
<td>F: 250-822-6178</td>
</tr>
<tr>
<td>Surrey</td>
<td>Surrey Memorial Hospital in Family Birthing area</td>
<td>Ph: 604-930-7884</td>
</tr>
<tr>
<td>Vancouver</td>
<td>BC Women's Hospital in Diagnostic Ambulatory Program area</td>
<td>Ph: 604-875-2903 (call first to book appnt, then fax requisition), F: 604-875-3013</td>
</tr>
<tr>
<td>St. Paul's Hospital in Medical Imaging area</td>
<td>Ph: 604-806-4811</td>
<td></td>
</tr>
<tr>
<td>Gregs Associates (community imaging clinic)</td>
<td>Ph: 604-321-6774</td>
<td></td>
</tr>
<tr>
<td>Victoria</td>
<td>Victoria General Hospital in Medical Imaging area</td>
<td>F: 250-381-8053</td>
</tr>
<tr>
<td>Royal Jubilee Hospital in Medical Imaging area</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Island Ultrasound (VIA/IA-operated ultrasound clinic)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**DID YOU KNOW THAT...**

...You can help us ensure that we provide you and your patient the most accurate risk estimate by:
- Indicating on the lab requisition if your patient will be having an NT and if known, at what NT site. We will then make sure we have the NT data when calculating the risk.
- Using the new lab requisition form (included) and carefully answering all questions.

...You can order more copies of the patient pamphlets (that have now been translated in Traditional Simplified Chinese, and Punjabi) on our website www.bcprenatalscreening.ca (click on the For Health Care Providers tab.)

...Our website has a “dating” tool, (found on the Home page) which was designed to help patients know what they are eligible for and when these tests are done. You may find this tool helpful too!
UTILIZATION OF PREGNATAL SCREENING TESTS

Since SIPS became available to all women in February 2009, the Prenatal Biochemistry Laboratory has seen a progressive increase in the utilization of SIPS with a decrease in the utilization of Quad.

This is a GOOD change in clinical practice since SIPS has a lower false positive rate than Quad.

---

**ESTIMATED 2009 UPTAKE OF SCREENING IN SINGLETON PREGNANCIES AND TYPE OF SCREENING TESTS USED**

<table>
<thead>
<tr>
<th>Age</th>
<th>2009 number of screens performed</th>
<th>Screening Test</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>percent of pregnancies screened</td>
<td>Quad</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SIPS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IPS</td>
</tr>
<tr>
<td>&lt;35</td>
<td>15,557</td>
<td>44%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>58%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>41%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1%</td>
</tr>
<tr>
<td>35 – 39</td>
<td>5,640</td>
<td>70%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>33%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>59%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8%</td>
</tr>
<tr>
<td>40+</td>
<td>1,026</td>
<td>57%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>29%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>49%</td>
</tr>
</tbody>
</table>

Amongst the 35 – 39 year old women, approximately 67% of them have SIPS or IPS and 33% have Quad. In contrast, amongst the <35 year old women, only 42% have SIPS or IPS and 58% have Quad.

We could improve screening by educating and encouraging pregnant patients to see their health care provider early in their pregnancy (before 18 weeks gestation). This will give them the option of having a screening test with a lower false positive rate (such as SIPS or IPS) and thus less chance of being offered an amniocentesis to have a definite diagnosis.

---

**FREQUENTLY ASKED QUESTIONS**

Is screening for Trisomy 18 still being done as no risk is displayed on the reports?

Yes. The program still screens for trisomy 18 but the software used does not display the risk for Trisomy 18 unless it is above the screen cut-off (1:300).

Why do the different screening tests have different risk cut-offs?

For any given screening test, a risk cut-off is set such that a desired detection rate is reached with an acceptable false positive rate. The different risk cut-offs chosen for Quad, SIPS and IPS were selected so that each test reached an equivalent detection rate. One can do that with a risk cut-off of 1:200 for IPS, 1:300 for SIPS and 1:385 for Quad. With these cut-offs, the false positive rate will be different for the different tests with the lowest false positive rate with IPS and the highest with Quad.

Can a detailed second trimester ultrasound (18 – 20 weeks) be used to modify the risk of Down syndrome assessed by the screening?

Yes. An 18 – 20 week ultrasound without any soft markers or anomalies is capable of reducing the estimated risk of trisomy 21 by approximately 50%.

How do I counsel a patient who is found on the 18 – 20 week ultrasound to carry a fetus with a choroid plexus cyst(s) (CPC)?

The finding of isolated choroid plexus cyst(s) (CPC) on ultrasound should be interpreted in conjunction with the prenatal screening (SIPS, IPS, or Quad) result or age alone if the woman is greater than 20+6 weeks gestation and Quad screen cannot be offered.

The risk of trisomy 18 in the presence of isolated CPC remains low if the screening test was negative and the woman is less than 35 years old. In those situations, women should be reassured. An amniocentesis should be offered only if the CPC is seen in association with either (a) a screen positive result for Down syndrome or trisomy 18; or (b) another abnormality(ies) on ultrasound; or (c) a woman 35 years or older.

How can a test performance of IPS, SIPS, or Quad be assessed by the screen?

The performance of the tests may be useful in counselling patients prior to screening and help patients decide whether to have screening and which screening test they may want to have.

It helps patients understand that:

- For all screening tests, a negative test result is reassuring as the remaining risk of Down syndrome would be low.
- Screening tests have different false positive rates with the lowest rate being with IPS, followed by SIPS and Quad.

This means that if a woman has a screening test that combines first and second trimester screening (IPS or SIPS), her chance of being offered an amniocentesis for a definite diagnosis is lower than if she has a Quad test.

Why do (according to the tables provided) women with a negative test result have such a low chance (<0.1%) of having a baby with Down syndrome if the detection rates range from 76% to 97%?

The incidence of Down syndrome is 1 in 700 (range from 1 in 1,250 in 25-year old women to 1 in 94 in 40-year old women). Given this incidence, if the screening tests detect 76% to 97% of cases, as a group, the women with negative screen results are left with a chance of Down syndrome of less than 1 in 1000 (3 – 24% of their original chance depending on the age of the woman and the test used). The screening tests have a very high negative predictive value ~99.9%. As a group, women who screen negative have a 99.9% chance that their baby is unaffected.

In practical terms, what does the screen positive rate mean?

The screen positive rate is the chance that a test will be above the screen cut-off and the result will be reported as screen positive. This rate includes both false positives and true positives. A false positive means that the screen is positive but the baby is unaffected whereas a true positive means that the pregnancy screens positive and the baby is affected. The screen positive rate varies for the different tests and for women of different ages. However, for all tests and all age groups, the majority of women who screen positive have an unaffected pregnancy.

For example, women less than 35 years of age, who choose SIPS, have a 3.7% chance of having a screen positive result. Of those who screen positive, 57% of them will have an unaffected pregnancy. These women have a false positive screen result.

In practical terms, once a woman has a positive screen result, should she be counselled as per the risk estimate on her report?

Yes. The risk estimate provided on her report is the best estimate of her risk for having an affected pregnancy based on the combination of her age, the results of her blood test(s) and, if available, the nuchal translucency measurement. The patient’s calculated risk as indicated on her report should be used in the counselling.

For example, the 32 year old woman who had SIPS and screens positive with a risk of Down syndrome of 1 in 240 should be counselled that the best estimate of her risk is 1 in 240. This means that for 240 women with this same risk, one will have an affected baby and 239 will not.